

REMARKS

Claims 1-35 and 43-51 remain pending. Applicants appreciate the indication that Claims 8-35 and 43-51 stand allowed.


Favorable reconsideration of the remaining pending claims is respectfully requested in view of the following remarks.

Claim Rejection under 35 USC 102

Claims 1 and 5-7 stand rejected as anticipated under 35 USC 102(e) by US Patent No. 6,660,410 to Hosokawa et al. ("Hosokawa"). Applicants respectfully traverse.


The Examiner alleges that the following Hosokawa compound reads on the rejected claims when X1 is formula (c) and n is 2.

Hosokawa




Claim 1

Formula 1: $X_1-(A_1)_n$, wherein A1 is a carbazole derivative:




XI can be defined by Formula (c):



R₃₁, R₃₃, and R₃₄ independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, a cyano group, a hydroxyl group, a substituted or unsubstituted alkenyl group, or a halogen atom, and wherein R₃₂ represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, a cyano group, a hydroxyl group, a substituted or unsubstituted alkenyl group, or a halogen atom, provided R₃₁ through R₃₄ are not simultaneously hydrogen atoms.

Structurally, the compound of Formula 1 as defined by (c) would be:



However, as discussed in Applicants last response, Claim 1 was previously amended such that the Markush listing for **R₃₂** *does not include a substituted or unsubstituted aryl group*.

In view of the foregoing the rejection is requested to be withdrawn.

Claim Rejection under 35 USC 103

Claims 1-4 stand rejected as unpatentable over Hosokawa to in view of U.S. Patent No. 6,960,364 to Suzuri et al. ("Suzuri"). Applicants' respectfully traverse.


For reasons discussed above, Hosokawa fails to teach or suggest an electroluminescent layer comprising, *inter alia*, a component layer of Formulae I and II as claimed. The carbazole derivative as taught by Hosokawa are excluded for reasons discussed above. Suzuri fails to compensate for the deficiencies of Hosokawa.

Accordingly, the rejection is requested to be withdrawn.

It is believed that the foregoing amendments and remarks fully comply with the Office Action and that the claims herein should now be allowable to Applicants. Accordingly, reconsideration and allowance are requested.

If there are any additional charges with respect to this Amendment or otherwise, please charge them to Deposit Account No. 06-1130.

Respectfully submitted,

By 
Peter R. Hageris
Registration No. 42,618

Date: July 12, 2007

CANTOR COLBURN LLP
1180 Peachtree Street, Suite 2050
Atlanta, GA 30309
Telephone (404) 607-9991
Facsimile (404) 607-9981
Customer No.: 23413